MitoPrime 120mg NAD+ / MOTS-c / 5-Amino-1MQ

MitoPrime 120 mg is a multi-component lyophilized research formulation containing NAD+, MOTS-C and 5-Amino-1MQ, developed for controlled scientific investigation and laboratory experimentation. Unlike a single-compound research product, MitoPrime combines three analytically distinct components within one formulation. Each component has been separately quantified and evaluated for purity and identity by independent third-party laboratory analysis. For research use only — not for human or veterinary use.  

Product Overview

MitoPrime 120 mg combines NAD+, MOTS-C and 5-Amino-1MQ within a single lyophilized research preparation. The formulation provides researchers with a multi-component material for controlled investigations involving cellular biochemistry, molecular signalling, mitochondrial research and metabolic pathway analysis. Independent third-party laboratory analysis by Liquilabs s.r.o. Czechia separately evaluated the individual components rather than reporting only a single result for the complete formulation. Assay testing measured 106.7 mg of NAD+, 10.53 mg of MOTS-C and 10.37 mg of 5-Amino-1MQ within the analysed production batch. Chromatographic purity was also determined individually. NAD+ was reported at 99.5 percent purity, MOTS-C at 96.4 percent purity and 5-Amino-1MQ at greater than 99.8 percent purity. In addition to assay and purity analysis, all three components underwent individual retention-time identification and molecular ion mass analysis. The production batch was further evaluated for bacterial endotoxins, microbiological quality and elemental impurities. This extensive analytical programme provides researchers with detailed batch-specific information concerning the individual constituents of MitoPrime rather than relying on a general purity statement for the complete formulation.  

Multi-Component Research Formulation

Multi-component research formulations require additional analytical consideration because the overall presence of material within a vial does not independently establish the quantity, purity or identity of every stated constituent. For MitoPrime, the three principal components were therefore evaluated separately:

• NAD+: 106.7 mg assay content with 99.5 percent purity
• MOTS-C: 10.53 mg assay content with 96.4 percent purity
• 5-Amino-1MQ: 10.37 mg assay content with purity greater than 99.8 percent

The three measured assay quantities total approximately 127.6 mg. The product itself is identified in the batch-specific Certificate of Analysis as MitoPrime 120 mg. Each component additionally underwent individual retention-time identification and mass-spectrometry analysis, providing researchers with multiple analytical data points for evaluating the composition of the tested formulation.  

NAD+ Research Component

NAD+ is one of the three independently characterised components contained within MitoPrime. Within biochemical research, NAD+ is studied in connection with cellular biochemical processes, molecular reactions and metabolic pathway systems. For this MitoPrime production batch, independent laboratory assay analysis measured 106.7 mg of NAD+. Chromatographic purity analysis reported 99.5 percent purity. Retention-time identification for the NAD+ component was reported at 0.987, providing an additional analytical identity parameter alongside assay and purity determination. Mass-spectrometry analysis additionally reported molecular ion mass identification at 2170 Da for the material identified as NAD+ within the Certificate of Analysis. These results provide multiple independent analytical measurements relating specifically to the NAD+ component of the tested MitoPrime production batch.  

MOTS-C Research Component

MOTS-C represents the peptide component of the MitoPrime research formulation and is investigated within experimental research involving mitochondrial biology, cellular signalling and metabolic molecular pathways. Independent laboratory assay analysis measured 10.53 mg of MOTS-C within the tested production batch. Chromatographic purity was reported at 96.4 percent. This value is reported transparently according to the independent Certificate of Analysis and should be considered separately from the higher purity results obtained for the other components. Retention-time identification for MOTS-C was reported at 0.994. Mass-spectrometry analysis additionally reported molecular ion mass identification at 663 Da for the MOTS-C component. Reporting the individual MOTS-C assay, purity and identity measurements provides considerably greater analytical transparency than describing MitoPrime with a single overall purity percentage.  

5-Amino-1MQ Research Component

5-Amino-1MQ is the third independently analysed component contained within MitoPrime. It is included as a defined research compound for controlled biochemical and molecular investigations. Independent assay testing measured 10.37 mg of 5-Amino-1MQ within the analysed production batch. Chromatographic purity was reported as greater than 99.8 percent. Retention-time identification produced a reported result of 0.983, while mass-spectrometry analysis reported molecular ion mass identification at 159 Da. Together, assay determination, chromatographic purity, retention-time identification and mass-spectrometry analysis provide multiple analytical parameters relating specifically to the 5-Amino-1MQ component.  

Scientific and Research Context

MitoPrime brings together three analytically distinct research compounds within a single formulation. This makes the product relevant to controlled experimental models where researchers are investigating multiple molecular components within the same laboratory system. The individual components are associated with different areas of biochemical, mitochondrial, peptide and metabolic research. Their inclusion within one research formulation allows the combined material to be investigated while retaining analytical documentation for each principal constituent. Importantly, the Certificate of Analysis does not establish clinical efficacy, therapeutic effects or outcomes in humans. The analytical documentation characterises the composition and quality parameters of the tested research material. The research contexts described for MitoPrime therefore relate exclusively to experimental scientific investigation.  

Research Focus

Within controlled laboratory environments, MitoPrime may be investigated in experimental models involving cellular and biochemical systems. Potential research areas include:

• Mitochondrial biology research
• Cellular biochemical pathway investigations
• Metabolic signalling research
• Molecular interaction studies
• Peptide-associated signalling investigations
• Comparative metabolic research
• Multi-component biochemical analysis
• Cellular pathway studies
• Controlled in vitro research

These areas describe research contexts only and do not represent established therapeutic, diagnostic or clinical applications.  

Analytical Verification (COA)

This production batch of MitoPrime 120 mg underwent independent third-party laboratory analysis by Liquilabs s.r.o. Czechia. The analytical programme separately evaluated NAD+, MOTS-C and 5-Amino-1MQ for assay content, chromatographic purity and identity, while additional batch-level testing evaluated microbiological quality, bacterial endotoxins and elemental impurities. Batch: GF-MITO-B241

• Product Identification: MitoPrime 120 mg
• NAD+ Assay: 106.7 mg
• NAD+ Purity: 99.5 percent
• NAD+ Retention Time Identification: 0.987
• NAD+ Molecular Ion Mass Identification: 2170 Da
• MOTS-C Assay: 10.53 mg
• MOTS-C Purity: 96.4 percent
• MOTS-C Retention Time Identification: 0.994
• MOTS-C Molecular Ion Mass Identification: 663 Da
• 5-Amino-1MQ Assay: 10.37 mg
• 5-Amino-1MQ Purity: greater than 99.8 percent
• 5-Amino-1MQ Retention Time Identification: 0.983
• 5-Amino-1MQ Molecular Ion Mass Identification: 159 Da
• Bacterial Endotoxins: 0.078 EU/mg
• Total Aerobic Microbial Count: 0 CFU/g
• Total Yeast and Mold Count: 0 CFU/g

The separate analytical characterisation of the three components provides a detailed batch-specific profile of the tested MitoPrime formulation.  

Assay Verification

Assay analysis determines the measured quantity of each target compound present within the analysed material. For this MitoPrime production batch, independent laboratory analysis measured:

• 106.7 mg NAD+
• 10.53 mg MOTS-C
• 10.37 mg 5-Amino-1MQ

Combined, these reported assay values represent approximately 127.6 mg of the three individually measured components. Reporting each assay result separately is particularly important for a multi-component formulation because a single total-weight measurement would not establish the amount of each constituent.  

Purity Verification

Chromatographic purity was independently evaluated for each of the three principal components.

• NAD+: 99.5 percent purity
• MOTS-C: 96.4 percent purity
• 5-Amino-1MQ: greater than 99.8 percent purity

These results demonstrate why multi-component formulations should not be represented by a single general purity percentage. Each compound has its own independently measured analytical profile. Grail Formula therefore reports the individual results transparently rather than applying the highest measured purity value to the entire formulation.  

Identity Verification

Identity analysis provides additional analytical information beyond assay content and chromatographic purity. Individual retention-time identification was reported for all three components:

• NAD+: 0.987
• MOTS-C: 0.994
• 5-Amino-1MQ: 0.983

These individual measurements provide additional analytical data supporting the identification of each stated component within the tested production batch.  

Mass Spectrometry Analysis

Mass spectrometry provides an additional molecular identity parameter by analysing the molecular ion mass associated with the compounds present within the tested material. For this MitoPrime production batch, the Certificate of Analysis reports:

• NAD+: 2170 Da
• MOTS-C: 663 Da
• 5-Amino-1MQ: 159 Da

These values are reported here exactly according to the batch-specific analytical documentation and form part of the broader independent identity assessment.  

Microbiological Testing

Microbiological analysis was performed as an additional component of the independent quality assessment. The analysed MitoPrime production batch produced the following results:

• Total Aerobic Microbial Count: 0 CFU/g
• Total Yeast and Mold Count: 0 CFU/g

No colony-forming units were reported for either of the microbiological parameters within the tested sample. Microbiological analysis complements the component-specific assay, purity and identity measurements and forms part of the complete batch-specific analytical profile.  

Bacterial Endotoxin Analysis

Bacterial endotoxin analysis was included within the independent laboratory testing programme for MitoPrime. The tested production batch produced a bacterial endotoxin result of 0.078 EU/mg. This result is documented alongside microbiological testing and the individual analytical measurements for NAD+, MOTS-C and 5-Amino-1MQ. Including bacterial endotoxin analysis provides researchers with an additional batch-specific analytical parameter beyond compound identity and chromatographic purity.  

Elemental Impurity Testing

Independent elemental impurity screening was also performed as part of the broader analytical programme. The tested elements included:

• Arsenic
• Cadmium
• Mercury
• Lead
• Nickel
• Vanadium
• Cobalt

Each of the tested elemental impurities was reported at less than 0.001 ppm. This screening complements assay determination, purity analysis, identity verification, mass-spectrometry analysis, microbiological testing and bacterial endotoxin analysis.  

Research Applications

MitoPrime 120 mg is supplied exclusively for controlled scientific investigation and may be utilised in appropriate experimental laboratory models involving molecular, mitochondrial and biochemical research. Potential research contexts include:

• Mitochondrial research models
• Cellular biochemical investigations
• Metabolic pathway research
• Molecular signalling studies
• Peptide research
• Multi-compound interaction investigations
• Comparative biochemical research
• Cellular pathway analysis
• Controlled in vitro experimentation

These applications relate exclusively to laboratory and scientific investigation.  

Comprehensive Multi-Component Verification

A defining analytical characteristic of MitoPrime is that its three principal components have been separately evaluated rather than treating the formulation as a single unidentified mixture. Independent third-party analysis includes:

• Individual assay determination for NAD+
• Individual assay determination for MOTS-C
• Individual assay determination for 5-Amino-1MQ
• Individual chromatographic purity assessment for NAD+
• Individual chromatographic purity assessment for MOTS-C
• Individual chromatographic purity assessment for 5-Amino-1MQ
• Individual retention-time identification for all three components
• Individual molecular ion mass analysis for all three components
• Bacterial endotoxin analysis
• Total Aerobic Microbial Count testing
• Total Yeast and Mold Count testing
• Elemental impurity screening
• Batch-specific analytical traceability

This comprehensive approach provides researchers with considerably more information about the tested formulation than a single overall purity or total-content measurement.  

Grail Formula Quality

Grail Formula places particular emphasis on independent third-party analytical verification, transparent batch documentation and measurable laboratory data. For multi-component research formulations such as MitoPrime, this approach is especially important because each constituent can possess a different assay content, chromatographic purity and analytical identity profile. Rather than applying a general specification to the complete formulation, the individual analytical results are reported transparently. For this production batch, this means clearly distinguishing between 99.5 percent purity for NAD+, 96.4 percent for MOTS-C and greater than 99.8 percent for 5-Amino-1MQ. Liquilabs s.r.o. Czechia additionally performed identity, microbiological, bacterial endotoxin and elemental impurity testing, resulting in comprehensive batch-specific analytical documentation.  

When You Choose Grail Formula

When selecting Grail Formula, researchers receive research compounds and formulations supported by independent third-party analytical documentation and batch-specific traceability. Our quality approach focuses on measurable analytical results rather than unsupported general purity claims. This is particularly relevant for MitoPrime because the formulation contains three analytically distinct components. Each principal component has been individually quantified, individually assessed for chromatographic purity and individually evaluated using retention-time and mass-spectrometry analysis. The production batch additionally underwent microbiological analysis, bacterial endotoxin testing and elemental impurity screening. The complete Certificate of Analysis allows researchers to review the underlying analytical results associated with the tested MitoPrime production batch directly.  

Storage and Laboratory Handling

MitoPrime 120 mg is supplied in lyophilized form for controlled laboratory research. Appropriate laboratory storage procedures should be followed to preserve the integrity of the research material. The formulation should be handled only by qualified research personnel using established laboratory procedures appropriate for multi-component biochemical and peptide research materials. Any preparation or experimental handling should take place exclusively within a suitable controlled laboratory environment and in accordance with the requirements of the intended research protocol.  

Research Use Limitation

• Intended solely for laboratory and in vitro research
• Not approved for human consumption
• Not approved for veterinary use
• Not intended for self-administration
• Not intended for diagnostic purposes
• Not intended for therapeutic applications
• Not intended to prevent or treat any disease
• Not permitted for clinical administration
• For research use only

MitoPrime 120 mg is supplied exclusively as a research formulation. All product information and analytical documentation are provided solely for scientific and laboratory purposes.

• Multi-component NAD+, MOTS-C and 5-Amino-1MQ research formulation
• Independently analysed by Liquilabs s.r.o. Czechia
• NAD+ assay content verified at 106.7 mg
• MOTS-C assay content verified at 10.53 mg
• 5-Amino-1MQ assay content verified at 10.37 mg
• NAD+ purity confirmed at 99.5%
• MOTS-C purity confirmed at 96.4%
• 5-Amino-1MQ purity confirmed at greater than 99.8%
• NAD+ retention-time identification confirmed at 0.987
• MOTS-C retention-time identification confirmed at 0.994
• 5-Amino-1MQ retention-time identification confirmed at 0.983
• NAD+ molecular ion mass identification reported at 2170 Da
• MOTS-C molecular ion mass identification reported at 663 Da
• 5-Amino-1MQ molecular ion mass identification reported at 159 Da
• Bacterial endotoxin level measured at 0.078 EU/mg
• Total Aerobic Microbial Count measured at 0 CFU/g
• Total Yeast and Mold Count measured at 0 CFU/g
• Arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt all measured below 0.001 ppm
• All three components individually evaluated for assay, purity and identity
• Complete batch-specific third-party analytical documentation
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.